ALEXION PHARMACEUTICALS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |
|---|---|---|---|---|---|---|
| Revenue | $1.44B | $1.14B | $4.13B | $3.55B | $3.08B | $2.60B |
| Operating income | $695.5M | $516.8M | $269.6M | $627.4M | $667.4M | $536.7M |
| Net income | $557.6M | $587.9M | $77.6M | $443.3M | $399.4M | $144.4M |
| Total assets | $18.10B | $17.54B | $13.93B | $13.58B | $13.25B | $13.10B |
| Total liabilities | $6.45B | $6.27B | $4.77B | $4.69B | $4.56B | $4.84B |
| Equity | $11.65B | $11.27B | $9.17B | $8.89B | $8.69B | $8.26B |
| EPS (diluted) | $2.50 | $2.61 | $0.35 | $1.97 | $1.76 | $0.67 |
| Shares out. | 221.4M | 223.5M | 221.7M | 224.6M | 225.3M | 202.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- 48.1%
- Net margin
- 38.6%
- Return on equity
- 4.8%
- Return on assets
- 3.1%
- Return on capital (ROCE)
- 4.2%
- Liabilities / assets
- 35.6%
- Debt / equity
- 0.55×
- Book value / share
- $52.62
- Revenue growth (YoY)
- 26.7%
- Net income growth (YoY)
- −5.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Altman Z″ (distress)
- 4.62safe
- Accruals / assets
- −13.5%clean
- Beneish M-Score
- -2.95normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 6 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 9, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2024-11-15Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
- Phase 3Active Not Recruitingreadout ~2025-04-08A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
- Phase 3Active Not Recruitingreadout ~2025-05-10A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
- Phase 3Active Not Recruitingreadout ~2025-05-27Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
- Phase 3Active Not Recruitingreadout ~2025-07-09Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
- Phase 3Active Not Recruitingreadout ~2025-07-23Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
- Phase 1Active Not Recruitingreadout ~2025-10-09Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
- Phase 3Recruitingreadout ~2026-01-05Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Coughlin Christopher JDirector | Jul 21, 2021 | D | 42,347 | $0.00 |
| Sarin AradhanaOfficer — EVP, CFO | Jul 21, 2021 | D | 120,253 | $0.00 |
| Friedman Paul ADirector | Jul 21, 2021 | D | 12,840 | $0.00 |
| Reinsdorf Judith ADirector | Jul 21, 2021 | D | 14,150 | $0.00 |
| Dunsire DeborahDirector | Jul 21, 2021 | D | 14,629 | $0.00 |
| Carino TanishaOfficer — EVP & CCAO | Jul 21, 2021 | D | 59,226 | $0.00 |
| Mollen John TDirector | Jul 21, 2021 | D | 15,336 | $0.00 |
| Brennan David RDirector | Jul 21, 2021 | D | 20,873 | $0.00 |
| Goff BrianOfficer — EVP & Chief Commercial Officer | Jul 21, 2021 | D | 150,832 | $0.00 |
| Chiniara EllenOfficer — EVP & Chief Legal Officer | Jul 21, 2021 | D | 116,850 | $0.00 |
| Bazarko DanielOfficer — SVP, Controller, CAO | Jul 21, 2021 | D | 60,207 | $0.00 |
| Franchini Indrani LallOfficer — EVP, Chief Compliance Officer | Jul 21, 2021 | D | 116,075 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJul 22, 2021
- Results of operationsJul 20, 2021
- Shareholder vote · Other material eventMay 11, 2021
- Other material eventMay 4, 2021
- Results of operationsApr 30, 2021
- Other material eventMar 15, 2021
- Director / officer changeFeb 16, 2021
- Results of operationsFeb 4, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (4)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.